{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:30:07Z","timestamp":1760985007136},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Otorrinolaringol\u00f3gica Espa\u00f1ola"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.otorri.2014.02.014","type":"journal-article","created":{"date-parts":[[2014,6,21]],"date-time":"2014-06-21T02:45:39Z","timestamp":1403318739000},"page":"346-354","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Epistaxis y dabigatr\u00e1n, nuevo anticoagulante oral no antagonista de la vitamina K"],"prefix":"10.1016","volume":"65","author":[{"given":"Francisco Javier","family":"Garc\u00eda Callejo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"B\u00e9cares Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Calvo Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paz","family":"Mart\u00ednez Beneyto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Marco Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Marco Algarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.otorri.2014.02.014_bib0005","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"Camm","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.otorri.2014.02.014_bib0010","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1157\/13107118","article-title":"Prevalencia de fibrilaci\u00f3n auricular en la poblaci\u00f3n espa\u00f1ola de 60 o m\u00e1s a\u00f1os de edad. Estudio PREV-ICTUS","volume":"60","author":"Cea Calvo","year":"2007","journal-title":"Rev Esp Cardiol"},{"unstructured":"Grupo de trabajo; Subdirecci\u00f3n General de Compras de Farmacia y Productos Sanitarios de la Consejer\u00eda de Sanidad de la Comunidad de Madrid. Nuevos anticoagulantes para la prevenci\u00f3n del ictus en la fibrilaci\u00f3n auricular no valvular: Recomendaciones de la Comunidad de Madrid. Diciembre 2011. Disponible en: http:\/\/www.madrid.org\/cs.","key":"10.1016\/j.otorri.2014.02.014_bib0015"},{"year":"2011","author":"Polo Garc\u00eda","series-title":"50 preguntas y respuestas sobre manejo cl\u00ednico de dabigatr\u00e1n","key":"10.1016\/j.otorri.2014.02.014_bib0020"},{"unstructured":"Baquero Barroso MJ, Alvarez Cienfuegos A, Candela Marroqu\u00edn E; Oficina de Evaluaci\u00f3n de Medicamentos. Servicio Extreme\u00f1o de Salud. Dabigatr\u00e1n [en fibrilaci\u00f3n auricular no valvular]. Hoja de Evaluaci\u00f3n de Nuevos Medicamentos. 2011;(2). Disponible en: http:\/\/saludcomunitaria.files.wordpress.com\/2011\/11\/20110930.deofevalmto-hnft-dabigatrc3a1-fa-v10.pdf","key":"10.1016\/j.otorri.2014.02.014_bib0025"},{"key":"10.1016\/j.otorri.2014.02.014_bib0030","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.beha.2013.07.012","article-title":"Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation","volume":"26","author":"Kansal","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.otorri.2014.02.014_bib0035","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to asses 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.otorri.2014.02.014_bib0040","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.beha.2013.07.003","article-title":"Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery","volume":"26","author":"Quinlan","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.otorri.2014.02.014_bib0045","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.beha.2013.07.005","article-title":"New oral anticoagulants for the treatment of venous thromboembolism","volume":"26","author":"Agnelli","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.otorri.2014.02.014_bib0050","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3810\/pgm.2013.07.2683","article-title":"Novel oral anticoagulants: A review of new agents","volume":"125","author":"Wanat","year":"2013","journal-title":"Postgrad Med"},{"unstructured":"Drugcite.com. Dabigatran adverse events reported to the FDA over time. Disponible en: http:\/\/www.drugcite.com\/?q=DABIGATRAN","key":"10.1016\/j.otorri.2014.02.014_bib0055"},{"key":"10.1016\/j.otorri.2014.02.014_bib0060","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4236\/crcm.2013.21002","article-title":"Coagulopathy and extremely elevated PT\/INR after dabigatran etexilate use in a patiente with end-stage renal disease","author":"Kim","year":"2013","journal-title":"Case Reports Med"},{"issue":"Suppl 1","key":"10.1016\/j.otorri.2014.02.014_bib0065","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.thromres.2012.08.288","article-title":"Laboratory tests and the new oral anticoagulants","volume":"130","author":"Tripodi","year":"2012","journal-title":"Thromb Res"},{"unstructured":"European Medicines Agency. Disponible en: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/about_us\/general\/general_content_000235.jsp&mid=","key":"10.1016\/j.otorri.2014.02.014_bib0070"},{"key":"10.1016\/j.otorri.2014.02.014_bib0075","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.oooo.2013.05.001","article-title":"Dental management considerations for a patient taking dabigatran etexilate: A case report","volume":"116","author":"Romond","year":"2013","journal-title":"Oral Surg Oral Med Oral Pathol Radiol"},{"key":"10.1016\/j.otorri.2014.02.014_bib0080","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s13181-011-0178-y","article-title":"Dabigatran: Review of pharmacology and management of bleeding complicactions of this novel oral anticoagulant","volume":"7","author":"Ganetsky","year":"2011","journal-title":"J Med Toxicol"},{"key":"10.1016\/j.otorri.2014.02.014_bib0085","first-page":"103","article-title":"Clinical use of new oral anticoagulant drugs: Dabigatran and rivaroxaban","volume":"26","author":"Shammem","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.otorri.2014.02.014_bib0090","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.beha.2013.07.007","article-title":"Novel oral anticoagulants in secondary prevention of stroke","volume":"26","author":"Diener","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.otorri.2014.02.014_bib0095","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.beha.2013.07.008","article-title":"Novel oral anticoagulants in non-valvular atrial fibrillation","volume":"26","author":"Potpara","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.otorri.2014.02.014_bib0100","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.beha.2013.07.001","article-title":"Bleeding and antidotes in new oral anticoagulants","volume":"26","author":"Majeed","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.otorri.2014.02.014_bib0105","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.2146\/ajhp120055","article-title":"Reversal dabigatran-induces bleeding with a prothrombin complex concentrate and fresh frozen plasma","volume":"69","author":"Dumkow","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.otorri.2014.02.014_bib0110","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3949\/ccjm.80a.13025","article-title":"Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban","volume":"80","author":"Fawole","year":"2013","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.otorri.2014.02.014_bib0115","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ajem.2012.07.021","article-title":"Subconjuctival hemorrhage in a patient on dabigatran (Pradaxa)","volume":"31","author":"Nguyen","year":"2013","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.otorri.2014.02.014_bib0120","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/MOH.0b013e328363c170","article-title":"Treatment with novel oral anticoagulants: Indications, efficacy and risks","volume":"20","author":"Ghanny","year":"2013","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.otorri.2014.02.014_bib0125","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s11936-013-0238-5","article-title":"Treatment of bleeding complications when using oral anticoagulants for prevention of strokes","volume":"15","author":"Akwaa","year":"2013","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.otorri.2014.02.014_bib0130","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJMp1302834","article-title":"Dabigatran and postmarketing reports of bleeding","volume":"368","author":"Southworth","year":"2013","journal-title":"N Eng J Med"},{"key":"10.1016\/j.otorri.2014.02.014_bib0135","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/eurheartj\/ehs408","article-title":"Acute management of bleeding in patients on novel oral anticoagulants","volume":"34","author":"Siegal","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.otorri.2014.02.014_bib0140","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1373\/clinchem.2012.189704","article-title":"The laboratory and the new oral anticoagulants","volume":"59","author":"Tripodi","year":"2013","journal-title":"Clin Chem"},{"issue":"Suppl 1","key":"10.1016\/j.otorri.2014.02.014_bib0145","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/j.thromres.2012.08.286","article-title":"Do new oral anticoagulants require laboratory monitoring? The clinician point of view","volume":"130","author":"Samama","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.otorri.2014.02.014_bib0150","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.2146\/ajhp110644","article-title":"Epistaxis associated with dabigatran in an elderly patient with reduced creatinine clearance","volume":"69","author":"Viny","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.otorri.2014.02.014_bib0155","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3109\/15563650.2012.721888","article-title":"Chen hemorrhagic complications associated with dabigatran use","volume":"50","year":"2012","journal-title":"Clin Toxicol"}],"container-title":["Acta Otorrinolaringol\u00f3gica Espa\u00f1ola"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001651914000958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001651914000958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T06:20:44Z","timestamp":1538547644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001651914000958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0001651914000958"],"URL":"https:\/\/doi.org\/10.1016\/j.otorri.2014.02.014","relation":{},"ISSN":["0001-6519"],"issn-type":[{"type":"print","value":"0001-6519"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epistaxis y dabigatr\u00e1n, nuevo anticoagulante oral no antagonista de la vitamina K","name":"articletitle","label":"Article Title"},{"value":"Acta Otorrinolaringol\u00f3gica Espa\u00f1ola","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.otorri.2014.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Otorrinolaringolog\u00eda y Patolog\u00eda C\u00e9rvico-Facial. All rights reserved.","name":"copyright","label":"Copyright"}]}}